Daré Bioscience (DARE) H.C. Wainwright 28th Annual Global Investment Conference summary

Key milestones and commercial progress

• Two products are generating revenue in 2026: FloraSync LF5 vaginal probiotic (launched) and DARE to PLAY Sildenafil Cream (launching this quarter).

• DARE Health Hub serves as a unified online platform for product access, telehealth, and prescription fulfillment.

• Digital marketing and provider relationships drive targeted commercial growth and product awareness.

• Positive consumer feedback and strong pre-order interest for new product launches.

• Management team has experience in both development and commercialization, supporting transition to a commercial-stage company.

Pipeline and clinical development

• Ovaprene, a hormone-free monthly contraceptive, is in phase III with top-line data expected next year.

• DARE-HPV, targeting persistent high-risk HPV infection, is in phase II with data readout expected next year.

• Menopause hormone therapy intravaginal ring aims for commercialization in 2027; non-hormonal options are also in development.

• Progesterone vaginal ring for IVF and pregnancy maintenance is entering phase I with NIH grant support.

• Broad pipeline leverages non-dilutive funding, with over $75 million awarded since 2017.

Market opportunity and strategic focus

• Focused exclusively on evidence-based solutions for women's health, addressing under-researched therapeutic gaps.

• Large market opportunities exist in contraception, menopause, and sexual health.

• Women's health brands represent 27% of pharma brands with over $500 million in annual revenue.

• Telehealth and digital channels are central to expanding access and engagement.

• Non-dilutive funding from government and foundations is a key driver for advancing clinical programs.